Abbreviations
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CDR

:   complementarity determining region

ER

:   endoplasmic reticulum

GFP

:   green fluorescent protein

IgG

:   immunoglobulin

G MBP

:   maltose binding protein

NusA

:   N utilization substance A

Introduction {#s0001}
============

Various strategies are used to study the functions of newly discovered proteins, including gene-targeted knockout animals, targeted gene disruption in mammalian cells and knockdown techniques such as siRNA, shRNA, miRNA, CRISPR and TALEN. In addition to these methods, which are active on the nucleotide level, the use of dominant negative mutants or inhibitor molecules were the most widely used methods to interfere directly with protein function. Another method with fast growing relevance that avoids some of the problems encountered with the above technologies is the use of intracellular antibodies (intrabodies). The molecules can be selected and designed to be very specific to the target, which are advantages of the technology. Because they can be thoroughly characterized for specificity in biochemical assays before use in cells, they avoid off-target effects known from nucleotide-based methods, and they can be designed to selectively target splice variants, different isoforms or even one post-translational modification of a protein. Furthermore, the function of target proteins can be knocked down in specific cellular compartments exclusively, while their function remains intact in other cellular compartments, as recently demonstrated by the knockdown of Sec61 in endosomes while maintaining its function in the ER.^[@cit0001]^ Although intrabodies are typically seen as an experimental tool to reveal the function of proteins by interfering with their function, this approach is also reported to have therapeutic potential against viral infections^[@cit0002]^ brain diseases^[@cit0007]^ or cancer.^[@cit0011]^ Here, the various protein knockdown strategies mediated by intrabodies ([**Fig. 1**](#f0001){ref-type="fig"}) are reviewed. Figure 1.The intrabody approach for the generation of protein interference phenotypes. Antibody fragments containing the antigen binding domains (V regions) specific for a particular protein can be selected from antibody phage display libraries or other in vitro selection systems like bacterial, yeast, mammalian or ribosomal display libraries. Alternatively, the variable region genes can be obtained from hybridoma antibodies by PCR with consensus primers, RACE or PCR with adaptor ligated cDNA. Antibody fragments, typically in scFv format, are then cloned into a specific targeting vector allowing expression of the intrabody in the nucleus, cytoplasm or ER.

Types of Intrabodies {#s0002}
====================

Intrabodies are antibodies that bind intracellularly to their antigen after being produced in the same cell,^[@cit0015]^ in contrast to antibodies delivered to a living cell from the outside.^[@cit0022]^ Intracellular antibodies can be subdivided into 2 main subgroups according to their mechanism of action. These are: 1) cytosolic intrabodies (cyto-intrabodies) and 2) endoplasmic reticulum (ER) retained intrabodies (ER intrabodies). While cyto-intrabodies block targets in a neutralizing fashion in the cytosol, ER intrabodies knock down proteins in the secretory pathway even without the requirement for the antibody to be neutralizing. By addition of a suitable signal peptide, intrabodies can also be targeted to the nucleus or mitochondria ([**Fig. 2**](#f0002){ref-type="fig"}).^[@cit0015]^ Figure 2.Differences between cytoplasmic/nuclear intrabodies and ER intrabodies. Via their retention signal KDEL, ER intrabodies (**A**) retain antigens passing the ER by binding to them. As antibodies are naturally produced in the ER, no particular selection for special folding/stability properties is required. In contrast, cytoplasmic/nuclear intrabodies (**B**) need to fold correctly in the reducing milieu of the cytoplasm. Further, they need to be tested and screened to identify antibodies which are capable, in addition to binding, to neutralise or inactivate their target\'s activity in the cytoplasmic biochemical milieu.

As antibodies usually are produced in an oxidizing biochemical milieu and folded with the help of ER based chaperones, only a fraction of the repertoire of naïve IgGs can be correctly folded in the reducing environment of the cytoplasm, which does not allow the formation of disulfide bridges.^[@cit0025]^ However, there are numerous examples where intrabodies function against cytosolic targets including examples against EGFR,^[@cit0011]^ BCR-ABL,^[@cit0013]^ NSP5 from rotavirus,^[@cit0027]^ *Clostridium botulinum* neurotoxin proteases,^[@cit0028]^ core antigen of HBV,^[@cit0006]^ Bax,^[@cit0030]^ HIV-1 Vif,^[@cit0002]^ Etk-kinase^[@cit0012]^ or hungtingtin protein.^[@cit0007]^ It has also been shown that cyto-intrabodies can trace cellular components in living cells.^[@cit0031]^

Various approaches have been described for the selection and generation of cyto-intrabodies: 1) use of the intracellular antibody capture technology (IACT);^[@cit0033]^ 2) construction of single domain intrabodies;^[@cit0012]^ 3) expression of intrabody fusion proteins;^[@cit0037]^ 4) complementarity-determining region (CDR) grafting or introduction of synthetic CDRs into suitable preselected frameworks;^[@cit0043]^ and 5) selection of single-chain variable fragments (scFv) without disulfide bonds.^[@cit0007]^ If the functional expression of a particular antibody in the cytoplasm fails, introduction of externally produced antibodies into the cytosol has been proposed using methods such as protein transfection (profection), peptides as protein transduction domains, fusion to targeting proteins or the use of translocation sequences and endosome escape domains.^[@cit0023]^ However, it has been difficult to achieve endosomal escape and to reach the cytoplasm with most of these methods.^[@cit0024]^

In contrast to cyto-intrabodies, antibodies targeted to the ER are made in their native environment ([**Fig. 2**](#f0002){ref-type="fig"}), thus can be expected to be correctly folded with intact disulfide bridges forming in the oxidizing environment.^[@cit0050]^ ER intrabodies work by just retaining antigens that pass the secretory pathway. Typically, these are cell-surface molecules, secreted molecules, intravesicular receptors or Golgi-located glycosyltransferases (ref. 3).

ER intrabodies are targeted to the lumen of the ER by a secretory signal peptide, and fusion of the retention sequence KDEL or SEKDEL to their C-terminus prevents their secretion together with the antigen bound to it. The KDEL receptor substrate leaves the ER, is transported to the cis-Golgi apparatus where it binds to the ERD1 and ERD2 receptors which are then recycled back to the ER via COPI-coated vesicles.^[@cit0021]^ The ER intrabody-antigen complex may then be degraded via an ER-associated degradation (ERAD) pathway that is either proteasome-dependent or proteasome-independent.^[@cit0053]^

Nuts and Bolts: How to Make Intrabodies {#s0003}
=======================================

Intrabodies can be generated by cloning the respective cDNA from an existing hybridoma clone^[@cit0056]^ or more conveniently, new scFvs/Fabs can be selected from *in vitro* display techniques such as phage display ([**Fig. 1**](#f0001){ref-type="fig"}),^[@cit0058]^ which provide the necessary gene encoding the antibody from the onset and allow a more detailed predesign of antibody fine specificity.^[@cit0060]^ In addition bacterial-, yeast-, mammalian cell surface display and ribosome display can be employed.^[@cit0061]^ However, the most commonly used *in vitro* display system for selection of specific antibodies is phage display.^[@cit0059]^ In a procedure called panning (affinity selection), recombinant antibody phages are selected by incubation of the antibody phage repertoire with the antigen. This process is repeated several times leading to enriched antibody repertoires comprising specific antigen binders to almost any possible target. To date, in vitro assembled recombinant human antibody libraries have already yielded thousands of novel recombinant antibody fragments.^[@cit0058]^ Antibo-dy phage repertoires can be divided into 4 different types according to the origin of their frameworks and CDRs: immune, naïve, synthetic and semi-synthetic antibody libraries.^[@cit0070]^ Immune antibody libraries are constructed from antibody genes of B cells from immunized animals or infected patients by PCR, using IgG primers for the heavy and light chain. Nonimmune (also named naïve or universal) libraries are built up from natural, unimmunized, rearranged V genes (e.g., from the IgM B-cell pool.^[@cit0071]^ Synthetic antibody libraries are constructed entirely in vitro using oligonucleotides that introduce areas of complete or tailored degeneracy into the CDRs of one or more V genes.^[@cit0072]^ Semi-synthetic libraries combine natural and synthetic gene fragments encoding different parts of the scFv or Fab molecule.^[@cit0074]^

Conversion of scFvs from in vitro selection methods into an ER intrabody only requires a single cloning step into the ER-targeting vector, e.g., pCMV/myc/ER to add the CMV promoter, a secretory leader, the ER retention sequence and a *myc* tag.^[@cit0056]^ Additional reporter functions, like green fluorescent protein (GFP), can also be added by using bicistronic vector designs.^[@cit0075]^

From hybridoma cells, the variable V~H~ and V~L~ domains can be amplified from the hybridoma cDNA using 1) PCR amplification with consensus primers,^[@cit0057]^ 2) rapid amplification of cDNA-ends (RACE^[@cit0079]^), and 3) PCR amplification using adaptor-ligated antibody cDNA.^[@cit0080]^ RACE and adaptor-ligated antibody cDNA prevent mismatches that might occur if V~H~ and V~L~ are amplified by consensus primers. V~H~ and V~L~ can be assembled by overlapping PCR introducing a linker taken from phage sequences (Gly~4~Ser)~3~[@cit0056] or human proteins,^[@cit0059]^ and the assembled scFv will be cloned into a targeting vector to transport scFvs into specific cell compartments.^[@cit0081]^

The most commonly used format for intrabodies is the scFv, which consists of the H- and L-chain variable antibody domain (V~H~ and V~L~) held together by a short, flexible linker sequence (frequently (Gly~4~Ser)~3~),^[@cit0082]^ to avoid the need for separate expression and assembly of the 2 antibody chains of a full IgG or Fab molecule.^[@cit0083]^ Alternatively, the Fab format comprising additionally the C1 domain of the heavy chain and the constant region of the light chain has been used. Recently, a new possible format for intrabodies, the scFab, has been described.^[@cit0085]^ The scFab format promises easier subcloning of available Fab genes into the intracellular expression vector, but it remains to be seen whether this provides any advantage over the well-established scFv format. In addition to scFv and Fab, bispecific formats (for review, see ref. [@cit0086]) have been used as intrabodies. A bispecific Tie-2 x VEGFR-2 antibody targeted to the ER demonstrated an extended half-life compared to the monospecific antibody counterparts.^[@cit0087]^ A bispecific transmembrane intrabody has been developed as a special format to simultaneously recognize intra- and extracellular epitopes of the epidermal growth factor,^[@cit0089]^ combining the distinct features of the related monospecific antibodies, i.e., inhibition of autophosphorylation and ligand binding. Another intrabody format particularly suitable for cytoplasmic expression are single domain antibodies derived from camels^[@cit0036]^ or consisting of one human VH domain^[@cit0034]^ or human VL domain.^[@cit0007]^ These single domain antibodies often have advantageous properties, e.g., high stability; good solubility; ease of library cloning and selection; high expression yield in *E.coli* and yeast.

The intrabody gene is expressed inside the target cell after transfection with an expression plasmid or viral transduction with a recombinant virus. With respect to the vector technologies used to supply the antibody mRNA to the target cell, there seem to be few limitations because, in principle, all the usually functional vector-, promoter- and transfection systems for heterologous expression could be employed. Typically, the choice is aimed at providing optimal intrabody transfection and production levels. Microinjection of hybridoma derived or in vitro transcribed mRNA was used in initial proof of principle studies,^[@cit0092]^ but, due to more delicate RNA handling and very small number of transfected cells, this approach has not been used frequently.

Successful transfection and subsequent intrabody production can be analyzed by immunoblot detection of the produced antibody, but, for the evaluation of correct intrabody/antigen-interaction, co-immunoprecipitation from HEK 293 cell extracts transiently cotransfected with the corresponding antigen and intrabody expression plasmids may be used, or the antigen intrabody complex can be confirmed to be localized in the ER by co-staining with the ER marker calnexin.^[@cit0004]^

Examples for Functional Studies with Cytoplasmic Intrabodies {#s0004}
============================================================

A quite successful group of cytoplasmic intrabodies has been developed against proteins playing an important role in the brain and for Alzheimer\'s and Parkinson\'s disease. Using the intracellular antibody capture technology, antibodies against the microtubule-associated protein TAU found in neurofibrillary lesions of Alzheimer\'s disease brains has been selected.^[@cit0033]^ This large panel of anti-TAU intrabodies selected from a naïve human antibody library provides a useful tool to study TAU function in degenerating neurons and brains. Meli and colleagues^[@cit0010]^ selected conformation-sensitive intrabodies by IACT against Alzheimer\'s amyloid-β oligomers starting from a phage display library constructed from mice immunized with a truncated version of human amyloid-β peptide. Some antibodies recognized in vivo-produced amyloid-β peptide "deposits" in histological sections from human Alzheimer\'s disease brains and significantly inhibited amyloid-β peptide oligomer-induced toxicity. A human scFv against oligomeric α-synuclein that inhibits aggregation and prevents α-synuclein-induced toxicity was also isolated from a naïve antibody phage display library.^[@cit0009]^ α-Synuclein is a presynaptic neuronal protein that is linked genetically and neuropathologically to Parkinson\'s disease and other neurodegenerative disorders. Interestingly, an anti-α-synuclein clone selected from the same library by a novel biopanning technique based on atomic force microscopy showed an opposite effect compared with the scFv mentioned above. It bound to intracellular aggregates of misfolded ataxin-3 and a pathological fragment of huntingtin and accelerated aggregation of these 2 molecules and increased cytotoxicity.^[@cit0095]^ Intrabodies have furthermore been selected against the natural precursor of nerve growth factor (proNGF).^[@cit0096]^ These antibodies can be used for the analysis of intracellular trafficking and signaling of proNGF in living cells. Intrabodies against gephyrin playing a role in clustering receptors have also been selected.^[@cit0097]^ This strategy could be very useful because the gephyrin knockout mice lead to a lethal phenotype.

Other intrabodies are directed against kinases, for example against the cytoplasmic protein kinase Syk,^[@cit0098]^ or the respective domains of human epidermal growth factor receptor^[@cit0011]^ or against the BCR-ABL oncogenic protein.^[@cit0013]^ Blocking the function of the latter protein may neutralize the oncogenicity of BCR-ABL, and could be used as a potential therapeutic agent in Philadelphia chromosome-positive leukemias. An efficient antibody-caspase 3-mediated cell killing system based on antibody-caspase 3 fusion has been developed.^[@cit0099]^ In the future, this approach may be used to kill tumor cells expressing tumor-specific proteins. Intrabodies against intracellular kinase domains of cell surface receptors and intracellular kinases (in particular against phosphorylation sites) can also be useful to decipher signaling pathways.^[@cit0011]^ Furthermore, oncogenic transcription factors may be attractive targets to inhibit the transcription of oncogenic genes. An example is a functional intrabody against the yeast transcription factor GCN4.^[@cit0046]^

Another intrabody selected from a naïve antibody phage display library neutralized aggrecanase-2, a factor crucial in the development of osteoarthritis, and dose-dependently improved disease progression in an osteoarthritis mouse model.^[@cit0101]^ A cytoplasmic intrabody used to investigate the role of the rotavirus non-structural protein NSP5 in the virus replication cycle has been described.^[@cit0027]^ It was demonstrated that NSP5 is an essential element for the assembly of functional viroplasms. These intrabodies were selected from mice that had been immunized with recombinant GST-NSP5. Intrabodies have also been employed as a strategy to target rabies.^[@cit0102]^

Selection and Engineering of Intrabodies Suitable for Cytoplasmic Expression {#s0005}
============================================================================

In contrast to ER intrabodies, the prerequisite for a specific protein knockdown by a cytoplasmatic intrabody is that the antigen is neutralized/inactivated through the antibody binding ([**Fig. 2**](#f0002){ref-type="fig"}). As said above, any cytoplasmic intrabody approach will be compromised by failure of the antibody to fold correctly.^[@cit0025]^ Consequently, specialized assays or selection conditions have been proposed to increase the success rates. While the selection of cytoplasmic intrabodies is still often a time-consuming trial and error approach and no reliable standard procedure has emerged, 5 different approaches to generate suitable antibodies are described in detail here and in [**Table 1**](#t0001){ref-type="table"}: 1) In vivo selection of functional intrabodies in eukaryotes such as yeast and in prokaryotes such as *E.coli* (antigen-dependent and independent); 2) generation of antibody fusion proteins for improving cytosolic stability; 3) use of special frameworks for improving cytosolic stability (e.g., by grafting CDRs or introduction of synthetic CDRs in stable antibody frameworks); 4) use of single domain antibodies for improved cytosolic stability; and 5) selection of disulfide bond free stable intrabodies. Table 1.Strategies for the selection of functional cytoplasmic intrabodiesTechniqueOutcomeReference**1) In vivo selection of intrabodies in the absence/presence of antigen in yeast and in *E.coli***  Antigen independent selection for cytoplasmic expression in yeast and mammalian cells using interaction between transcription activator domain coupled to scFv and DNA binding domainSelection of stable frameworks from a human naïve antibody library^[@cit0103]^Antigen independent intrabody selection after export into the cytoplasm mediated by Tat (ISELATE).Isolation of soluble scFv variants from an insoluble parental sequence.^[@cit0106]^Modification of ISELATE method. Selection will be performed by analyzing inner membrane anchored Tat-scFv fusions of transfected spheroblasts with anti-FLAG antibody.Selection and affinity maturation of scFvs using error prone PCR resulted in scFvs with higher affinity than the original clones.^[@cit0107]^Intracellular Antibody Capture Technology based on an antigen-dependent 2 hybrid system. Cotransfection of antigen fused to DNA binding domain lexA and scFv fused to transactivator domain VP16 leads to selection of cytoplasmic active intrabodies.Selection of intrabodies against Tau, amyloid-β peptide,α-synuclein, proNGF, gephyrin, Syk, EGFR, BCR-ABL, caspase 3, aggrecanase-2, NSP5 from rotavirus^[@cit0033; @cit0010][@cit0009; @cit0096][@cit0097; @cit0098][@cit0011; @cit0013; @cit0099; @cit0101; @cit0027]^Antigen dependent selection of intrabodies in the *E.coli* cytoplasm based on co-expression of Tat signalpeptide-scFv and antigen-β-lactamase fusionSelection of antigen specific binders from a library of randomized CDR-H3 sequences.^[@cit0108]^**2) In vivo selection of stable intrabody fusion proteins**  Generation of scFv-protein fusionsFusion to MBP, GFP or the Fc domain are the most reliable strategies.^[@cit0041; @cit0039; @cit0037; @cit0040; @cit0042; @cit0038]^**3) CDR grafting or introduction of synthetic CDRs into stable frameworks**  Transplantation of CDRs from one antibody to a different stable antibody framework.\
Introduction of synthetic CDR loops into a stable human framework.\
Construction of a novel human VH domain antibody library with restricted randomizations at fixed positions in the CDR2 and CDR3, respectively.Generation of a framework stabilized version of an anti-GCN4 intrabody.\
Grafting several groups of residues in the CDRs important for antigen binding of scFv D1.3 into stable framework of scFvF8\
Construction of a synthetic antibody library based on the human framework of scFv13R4 by introducing synthetic CDR3 loops.\
Construction of a synthetic single human VH domain antibody library based on the framework of antibody HEL4. Selection of thermodynamically stable anti-lysozyme clones expressed in *E.coli*.^[@cit0046],^\
^[@cit0043],^\
^[@cit0045][@cit0044]^**4) Cytoplasmic intrabodies in the single domain format**  Generation of Camelid VH single domain antibodies from naïve or immune-camelid antibody repertoires\
Selection of stable human VH domains from naïve or synthetic VH domain antibody repertoires\
Selection of human VL domains from naïve or synthetic VL domain antibody repertoiresCamelid VH single domain antibodies against: F-actin capping protein CapG, β2-adrenergic receptor, Clostridium botulinum neurotoxin (BoNT) proteases, core antigen of HBV (HBcAg), 15-acetyldeoxynivalenol, caspase-3, Bax, nuclear polyA-binding protein, HIV-1 Vif\
Most of the VH domains isolated from a human germ-line V~H~ library by the ISELATE method resulted in soluble clones expressed in *E.coli*.\
Construction of a large human VH domain antibody repertoire by combinatorial assembly of CDR building blocks from a smaller repertoire comprising aggregation-resistant clones\
Selection of a human VL domain against Etk kinase from a large VL domain phage display library, derived from a single human framework of light chain\
Construction of a naïve VL domain library and isolation of clones recognizing B cell super-antigen protein L.\
Selection of an α-hungtingtin human VL domain intrabody from an original non-functional scFv. Affinity maturation of the original scFv was performed using error prone PCR and yeast surface display.^[@cit0014; @cit0100][@cit0029; @cit0028]^\
^[@cit0006; @cit0122][@cit0123; @cit0030][@cit0124]^\
^[@cit0090]^\
^[@cit0034]^\
^[@cit0012]^\
^[@cit0091]^\
^[@cit0008]^**5) Selection of scFvs without disulfide bonds**Isolation of cysteine free scFvs by phage display. After DNA-shuffling and Error prone PCR cysteine free variants of an α-levan antibody could be expressed functional in the cytoplasm of *E.coli*.\
Functional cysteine free VL domains recognizing hungtingtin protein could be selected by yeast surface display after Error prone PCR.^[@cit0047]^\
^[@cit0007]^ Table 2.ER intrabodies appliedFunction targetedTargetsOncogenic receptorsVEGFR 2,^[@cit0087; @cit0153; @cit0198; @cit0088]^ Tie-2,^[@cit0087; @cit0088; @cit0131]^ ErbB-2,^[@cit0145; @cit0147; @cit0150; @cit0155][@cit0199; @cit0200; @cit0201; @cit0202]^ EGFR,^[@cit0203]^ metalloproteinases MMP-1 and MMP-9,^[@cit0204]^ extracellular matrix metalloproteinase inducer,^[@cit0205; @cit0206]^ human α folate receptor,^[@cit0207]^ cathepsin L^[@cit0208]^ oncoprotein E7^[@cit0209]^Virus proteins to prevent virus assemblyHIV-1 gp120,^[@cit0210; @cit0211]^ HIV-1 gp 160,^[@cit0212]^ HBV precore antigen,^[@cit0213]^ HCV ApoB,^[@cit0214]^ HCV core protein,^[@cit0215]^ gp46 of maedivisna virus^[@cit0216]^Knockdown of cellular virus receptors to block virus entryCCR5,^[@cit0217; @cit0218; @cit0219]^ CXCR4.^[@cit0220; @cit0221]^Receptors of the immune systemMHC I,^[@cit0222; @cit0223; @cit0224]^ integrins,^[@cit0225; @cit0226; @cit0227]^ VCAM-1,^[@cit0134; @cit0149]^ NCAM,^[@cit0056]^ TLR2,^[@cit0004]^ TLR9,^[@cit0005]^ IL-2,^[@cit0148; @cit0151; @cit0228]^ CD147,^[@cit0229]^ IL-6^[@cit0230]^Nervous systemNeurotrophin Receptor p75,^[@cit0075]^ β-amyloid protein,^[@cit0132]^ β-amyloid precursor protein,^[@cit0154]^ cellular prion protein^[@cit0231; @cit0232]^

*Approach 1, intrabody selection strategies, in eukaryotes*. An antigen-independent selection method termed "Quality Control" was developed to identify intrabodies that are soluble in the cytoplasm of yeast and mammalian cells.^[@cit0103]^ For selection in yeast, the scFvs were fused to a transcriptional activation domain and a peptide derived from Gal11P binding to the transcription factor Gal4 (1--100) fragment. Soluble expression of the scFv mediates the specific interaction of peptide Gal 11P with the DNA-bound Gal4 (1--100) fragment and then transcription of *lacZ* and *HIS3* reporter genes can be activated, whereas insoluble scFvs are expected to result in non-functionality of the whole fusion protein and thus no activation of reporter genes occurs. Selection in mammalian cells, based on a similar principle, was implemented by employing scFv-VP16 fusions that bind to the DNA binding domain Gal4. Using the "Quality Control" approach, growth of colonies under selection conditions, indicating scFv clones that are stable and soluble in the cytosol, was below 1% among screened clones, which gives a rough initial estimate of the fraction of antibodies that can be expected to fold correctly in the cytoplasm.^[@cit0103]^

Yeast two-hybrid technology-based IACT is an antibody-dependent method employed to select suitable intrabodies from scFvs preselected by phage display. The pre-enriched antibody fragment library is fused to the VP16 transcription activation domain. Antigen-specific functional intrabodies are selected after co-transfection of the scFv-VP16 library with antigen coding sequence fused to the LexA DNA binding domain in yeast cells. Complex formation of the antigen and an antigen-specific scFv in the yeast cytoplasm leads to activation of yeast chromosomal reporter genes.^[@cit0033]^ A single pot library of intracellular antibodies (SPLINT) was generated by amplification of natural V regions from non-immunized mice and intrabodies selected against different antigens.^[@cit0104]^ A further modification of the original IACT technique was established to select for intrabodies that are able to interrupt protein-protein interactions.^[@cit0105]^ Concerning the IACT selection strategy, it is important that the source for intrabody selection (particularly naïve, immunized mouse antibody or naïve human antibody phage display repertoires have been employed) must have a very large diversity, because functional cytoplasmic intrabodies were described to be a very small subset of the total antibody repertoire.

*Approach 1, intrabody selection strategies, in prokaryotes*. Another in vivo selection strategy is the selection of functional cytoplasmic intrabodies fused to a selection marker in *E.coli* using the twin-arginine translocation (TAT) machinery. This strategy is referred to as [**i**]{.ul}ntrabody [**sel**]{.ul}ection [**a**]{.ul}fter [**T**]{.ul}at [**e**]{.ul}xport into the cytoplasm (ISELATE).^[@cit0106]^ Selection is provided by fusion of an N-terminal Tat-specific signal and C-terminal TEM1 β-lactamase to the coding region of the scFv. With the TAT signal providing the transport of folded proteins, only non-aggregated (therefore presumably correctly folded) intrabodies can be transported from the cytoplasm to the periplasm of *E.coli* where the fused ß-lactamase provides ampicillin resistance, hence positive selection of the respective clones. Recently, a variant of this selection approach for the isolation of correctly folded membrane-anchored scFvs was developed.^[@cit0107]^ Karlsson et al found that correctly folded scFvs fused to the Tat signal peptide are transported from the cytoplasm to the periplasm of *E.coli*, but remain N-terminally anchored with the Tat signal peptide to the inner membrane. Selection is performed with antibody expression plasmid transfected spheroplasts and anti-FLAG antibody, which can only recognize the FLAG epitope fused to the C-terminal end of the antibody if the N-terminal signal peptide is anchored in the inner membrane of *E.coli* and the scFv localized in the periplasm. Affinity maturation of selected scFvs using error prone PCR resulted in scFv clones expressed in the cytoplasm with higher affinity than the original clones.

A mixed strategy that combined elements described above was also developed in *E.coli*. In this case, the scFv is N-terminally fused to the Tat signal peptide ssTorA and coexpressed with the antigen C-terminally fused to the β-lactamase gene. It was observed that only those binding pairs that are correctly folded and functional in the cytoplasm could be exported to the periplasm and give rise to antibiotic resistant cells.^[@cit0108]^ Notably, intrabodies with high stability and high antigen-binding affinity could be selected from resistant bacterial clones on high concentrations of the antibiotic carbenicillin.^[@cit0109]^

*Approach 2, antibody fusion proteins*. Several publications proposed the addition of non-intrabody domains to enhance folding or stability of cytoplasmic intrabodies. One approach is to use GFP to improve folding of proteins, including recombinant antibody fragments, in *E.coli* and mammalian cells.^[@cit0037]^ It was shown that GFP variants fold differentially in prokaryotic and eukaryotic cells.^[@cit0110]^ Recently, scFv-GFP fusions were used to screen for intrabody solubility in mammalian cells by fluorescence activated cell sorting (FACS).^[@cit0039]^ Mammalian cells were transfected with GFP fusions by retroviral gene transfer, the GFP positive cells sorted and expression of the scFv-GFP fusions analyzed. The GFP signal correlated with soluble expression levels of the scFvs in the cytoplasm; however, only 2 different scFvs were tested. A GFP-tagged cytoplasmically expressed scFv was applied for in vivo labeling of tyrosinated α-tubulin and measurement of microtubule dynamics.^[@cit0037]^ It remains to be proven whether this strategy is broadly applicable.

In addition to GFP, a Cκ domain,^[@cit0111]^ maltose binding protein (MBP),^[@cit0041]^ N utilization substance A (NusA) ^[@cit0113]^ or Fc domain^[@cit0038]^ have been proposed as fusion partners, although few successful examples have been presented. Different labs have focused on the inhibition of p53 and activation of mutated p53 inside tumor cells.^[@cit0111]^ The anti-p53 intrabodies derived from hybridomas showed different stability inside the cytoplasm, as expected. One of the scFvs targeted to the nucleus or cytoplasm was expressed well as a fusion with the Cκ domain.^[@cit0111]^ Another scFv showed very low expression inside the cytoplasm after fusion with a Cκ domain.^[@cit0112]^ Interestingly, 2 intrabodies recognizing p53 mutants that were expressed in the nucleus and cytoplasm restored transcriptional activity of p53 mutants by themselves,^[@cit0114]^ which demonstrates that solubility depended on the properties of the intrabody rather than on the Cκ domain. Because degradation of proteins can be linked to the presence of regions rich in proline, glutamic acid, serine and threonine (PEST sequences),^[@cit0115]^ the low content of potential PEST sequences might explain the stability of some intrabodies such as the 2 anti-p53 mutated intrabodies.^[@cit0114]^ However, the fusion of a proteasome-targeting PEST motif to intrabodies recognizing Huntingtin or α-synuclein-mediated increase of intrabody stability and degradation of the corresponding antigen,^[@cit0116]^ demonstrating that no simple PEST sequence motif-related algorithm will predict the intrabody efficacy.

MBP has extensively been used to enhance folding of intrabodies inside the cytoplasm of *E.coli* and mammalian cells.^[@cit0041]^ It was found that the folding of some passenger proteins fused to MBP could be mediated by endogenous chaperones in vivo.^[@cit0118]^ It was proposed that the solubility-enhancing activity of MBP is mediated by its open conformation and it is assumed that the ligand-binding cleft is involved in the mechanism.^[@cit0119]^ However, the molecular mechanism of the process is not known, and some reports of improved folding may have been mistakenly based on the improved overall solubility of the fusion.

*Approach 3, CDR grafting or introduction of synthetic CDRs in stable frameworks*. Antigen-binding loops can be transplanted from one antibody to a different antibody framework, a procedure called CDR loop grafting.^[@cit0120]^ While the technology gained historical relevance by being used to de-immunize ("humanize") therapeutic antibodies, it also can be used to transfer a given specificity to a preselected V region framework with optimized production / folding / stability properties. A stable framework-engineered stabilized version of an anti-GCN4 antibody was cytoplasmically expressed as an scFv intrabody in yeast.^[@cit0046]^ This variant inhibited the activity of β-galactosidase expressed from a GCN4-dependent reporter gene compared to the unfolded original scFv. Another approach used the scFv(F8), which showed very high in vitro stability and functional folding in both the prokaryotic and eukaryotic cytoplasm.^[@cit0043]^ Several groups of residues in the CDRs important for antigen binding of the poorly stable anti-hen egg lysozyme (HEL) scFv(D1.3) were grafted into the framework of scFv(F8). Five different variants were constructed, and 4 of those could be expressed in the cytoplasm of *E.coli* and bind to the antigen after purification. The donor framework of scFv(F8) seems to be able to tolerate extensive CDR substitutions without loss of stability in the cytoplasm.^[@cit0045]^ A synthetic antibody library based on the human framework of anti-β galactosidase scFv13R4 was expressed in the *E.coli*, yeast and mammalian cell cytoplasm. Randomized CDR 3 loops were introduced in the framework by PCR and a number of functional cytoplasmic intrabodies against different antigens selected, including an intrabody that identified a protein of yet unknown function involved in mast cell degranulation.^[@cit0121]^ Another approach used amino acid randomization at 4 and 7 different positions in the CDR2 and CDR3 loop of the single domain VH of anti-lysozyme antibody HEL4.^[@cit0044]^ The library was used for selection of antibodies with different specificities on both purified lysozyme and whole cells.

*Approach 4, single domain antibodies*. Single domain antibodies are composed of only one V region, which could be either a variable domain of the heavy or light chain. They can be produced from conventional human IgGs (V~H~s and V~L~s), from camelid heavy-chain IgGs (V~H~Hs) and from cartilaginous fish IgNARs (V~NAR~s). As for scFvs, libraries of single domain antibodies can be constructed from naïve, synthetic, semi-synthetic, transgenic animals or immunized sources and clone selection is typically done by phage panning or yeast cell surface display. Despite providing only half of the binding surface of an antibody, camelid V~H~ single domain antibodies have demonstrated high affinity for many cognate antigens, high solubility and aggregation resistance. The camelid single domain antibodies are selected from camelid VHH naïve or immune libraries. Several camelid cytoplasmic single domain antibodies have been successfully generated, for example against F-actin capping protein CapG,^[@cit0014]^ β2-adrenergic receptor,^[@cit0100]^ *Clostridium botulinum* neurotoxin (BoNT) proteases,^[@cit0028]^ core antigen of HBV (HBcAg),^[@cit0006]^ 15-acetyldeoxynivalenol,^[@cit0122]^ caspase-3,^[@cit0123]^ Bax,^[@cit0030]^ and nuclear polyA-binding protein.^[@cit0124]^ A nanobody recognizing the F-actin capping protein CapG was generated after immunization of a llama.^[@cit0014]^ It was demonstrated that expression of the intrabody in breast cancer cells restrained cell migration and lung metastasis in a xenograft tumor mouse model. Anti-β2-adrenergic receptor single domain intrabodies from the Camelid family inhibiting G protein activation, G protein-coupled receptor kinase-mediated receptor phosphorylation and β-arrestin recruitment have been published.^[@cit0100]^ An intrabody against caspase-3 was isolated from a naïve phage display llama antibody repertoire.^[@cit0123]^ Single-domain antibodies against the proapoptotic Bax protein have been selected.^[@cit0030]^ These anti-Bax VH intrabodies could be used as tools for studying the role of Bax in oxidative-stress-induced apoptosis and for developing novel therapeutics for the degenerative diseases involving oxidative stress.

Yeast surface display has also been used to select camelid VHHs as immune inhibitors of *Clostridium botulinum* neurotoxin (BoNT) proteases. VHHs were selected from an immunized llama single domain repertoire that remained functional when expressed within neurons and bound to BoNT proteases with high affinity.^[@cit0029]^ VHHs from a non-immune llama single-domain library have been isolated.^[@cit0028]^ The X-ray crystal structure of the most potent intrabody in complex with the protease was solved and the structure revealed that the VHH binds in the α-exosite of the enzyme, far from the active site for catalysis. Camelid VHH domain antibodies selected from a non-immune llama single-domain phage display library prevented oculopharyngeal muscular dystrophy associated aggregation of nuclear poly(A)-binding protein.^[@cit0124]^ Notably, intrabodies also reduce the presence of already existing aggregates. VHH intrabodies against the hepatitis B core antigen (HBcAg) were selected from a single domain phage display library constructed from llamas immunized with noninfectious HBV particles.^[@cit0006]^ Intrabodies targeted to the nucleus affected HBcAg expression and trafficking in HBV-transfected hepatocytes. Camelid VHH domains selected from a hyper-immunized phagemid library were selected against toxin 15-acetyldeoxynivale.^[@cit0122]^ Expression of the corresponding intrabodies in yeast resulted in significant resistance to the toxin. The authors suggested that VHH expression in plants may lead to enhanced tolerance to mycotoxins. A camelized rabbit -- derived VH single-domain recognizing HIV-1 Vif was constructed starting from an original rabbit scFv.^[@cit0002]^ A set of 3 mutants of the derived VH single domain antibody with gradual increasing camelization was performed. There was a strong correlation between the improvement in protein solubility in mammalian cells and the gradual increasing camelization. The intrabodies neutralized HIV-1 infectivity. Anti-ß catenin llama single domain intrabodies that inhibit Wnt signaling were recently reported, providing a tool for further study of the Wnt pathway.^[@cit0125]^

In contrast to the V~H~ domains of camels and llamas, human heavy chain variable domains and human light chain variable domains are more prone to dimerization and aggregation and exhibit poor solubility.^[@cit0035]^ Nevertheless, several human single domain antibodies have been selected, for example against Etk kinase,^[@cit0012]^ huntingtin protein^[@cit0007]^ and B cell super-antigen protein L.^91^ As for scFvs, a Tat signal peptide and β-lactamase-based strategy was used to isolate human V~H~ domains from a human germ-line V~H~ library, with increased level of thermodynamic stability, reversible folding and soluble expression in *E.coli*.^[@cit0090]^ In another approach, aggregation-resistant human heavy chain variable domains were selected on phage by heat denaturation.^[@cit0126]^ A large human VH domain antibody repertoire was constructed by combinatorial assembly of CDR building blocks from a smaller repertoire comprising a high frequency of aggregation-resistant antibody domains.^[@cit0034]^ Barthelmy and colleagues^[@cit0127]^ evolved and analyzed stable human VH domains from a phage display antibody library. By building libraries comprising the framework of humanized anti-HER2 scFv and different diverse synthetic V~H~ CDR3 loops, they selected the most stably expressed V~H~ domains secreted in *E.coli* and then introduced mutations that increased the hydrophilicity of the former light chain interface by replacing exposed hydrophobic residues with structurally compatible hydrophilic substitutions. The stability of many in vitro evolved V~H~ domains seemed to be essentially independent from the CDR3 sequence and instead derived from mutations introduced in the second step.

A repertoire of stable human V~L~ domains was isolated after panning with a human naïve V~L~ library with B cell super-antigen protein L. Isolated clones exhibited improved reversibility of thermal unfolding after purification from the periplasm of *E.coli*.^[@cit0091]^ Nevertheless, it remains to be demonstrated whether the isolated variable domains can also be stably expressed in the cytoplasm as stable functional intrabodies. An α-hungtingtin single domain antibody comprising a human light chain variable domain (V~L~) was selected from an original nonfunctional scFv.^[@cit0008]^ Affinity maturation of the original scFv was performed using error-prone PCR and yeast surface display, and it was shown that the paratope was localized in the V~L~. However, this selection approach is only applicable when the binding energy of the scFv is provided predominantly by only one of the 2 V domains. A human V~L~ against Etk kinase was selected from a large single domain phage display library, derived from a single human framework of light chain.^[@cit0012]^ When expressed in Src-transformed cells, the single-domain antibodies interacted with endogenous Etk in the cytoplasm and efficiently blocked its kinase activity, leading to partial inhibition of cellular transformation.

*Approach 5, cyto-intrabodies without disulfide bridges*. Many stabilizing and destabilizing mutations in the framework or CDRs have been described.^[@cit0128]^ In this context, stable cysteine-free scFvs have been selected and expressed in functional form in the *E.coli* cytoplasm starting from the levan binding antibody ABPC48. Affinity maturation was performed using DNA-shuffling and random mutagenesis.^[@cit0047]^ An engineered single domain V~L~ antibody without disulfide-bridge and with high affinity preventing aggregation of huntingtin was selected after affinity maturation of the V~L~ domain of an original anti-huntingtin scFv using error-prone PCR and yeast surface display.^[@cit0007]^ These intrabodies may have therapeutic potential for the treatment of hungtingtin disease. However, no naïve library strategy has yet emerged from this interesting approach, limiting this method to the tedious optimization of individual antibody clones.

Targeting the "Outside" from the "Inside": The ER Intrabody Approach {#s0006}
====================================================================

The use of various signal sequences attached to antibody fragments allows its targeting specifically to different intracellular compartments. ER targeting in particular allows interference with the function of the members of the membrane and the plasma proteome (secretome), relying on a different mechanism than cytoplasmic antibodies. Hence, generation of suitable ER intrabodies is much easier because they do not require special folding or stability features, and, in particular, no neutralizing activity toward the antigen is needed. Reasonable antigen binding is sufficient ([**Fig. 2**](#f0002){ref-type="fig"}). This eliminates the necessity for any specialized selection strategy and allows immediate utilization of the vast and quickly growing resource of recombinant research antibodies currently generated.^[@cit0130]^

Reports of ER intrabodies published so far have shown protein knockdown in vitro and recently in vivo in a mouse model. As a step toward in vivo use, ER intrabodies have been applied in primary tissue explants (Zhang, Korte and Dübel, unpublished data) and against the oncogenic receptors VEGFR-2/KDR and Tie-2 in xenograft mouse tumor models.^[@cit0087]^ In addition ER intrabodies specific to amyloid-ß demonstrated an inhibition of amyloid-ß accumulation in an Alzheimer\'s disease mouse model.^[@cit0132]^ ER intrabodies have been applied for various purposes ([**Table 2**](#t0002){ref-type="table"}).

Intrabodies have also been used in plants to interfere with cell functions and plant cell-pathogen interactions.^[@cit0133]^ The first transgenic ER intrabody mouse that constitutively expresses an α-VCAM1 intrabody, resulting in a clear phenotype (aberrant distribution of immature B cells in blood and bone marrow), has recently been described.^[@cit0134]^ In the future, by using inducible or cell- and tissue specific promoters, this important approach will facilitate the functional analysis of proteins in specific subpopulations of cells or tissues, or with different time kinetics. Moreover, this study hinted at possible quantitative effects, which would allow regulation of knockdown strength.

A therapeutic application of intrabodies would require transfection systems allowing gene therapy, typically viral or non-viral systems.^[@cit0135]^ Despite growing numbers of clinical studies using gene therapy, some issues are yet unresolved, like risks from insertional mutagenesis^[@cit0136]^ or low gene transfer efficiency of nonviral vectors.^[@cit0137]^ The construction of retroviruses with low safety risk^[@cit0138]^ and the development of transductional and transcriptional targeting for cell-specific gene transfer^[@cit0139]^ are new promising approaches. Furthermore, gene therapy with mRNA might be possible in the future.^[@cit0140]^

Parameters Influencing the Efficiency of ER Intrabodies {#s0007}
=======================================================

ER antibodies work by retaining their antigen in the ER. For this simple approach, and despite publication of many successful cases, our systematic understanding of the many parameters involved in a successful knockdown by intrabodies is still very limited. The influence of target and antibody expression levels, antibody affinity and epitope structures is still largely unexplored. For instance, a study by Beerli et al^[@cit0141]^ reported efficient target knockdown by only one of 2 ER intrabodies with nanomolar affinity,^[@cit0141]^ which suggests that high affinity is not sufficient as a predictive criterion for successful ER intrabody-mediated knockdown. This is further supported by a report on the lack of correlation between the affinity and antineoplastic effect of anti-erbB2 targeting ER intrabodies.^[@cit0145]^ Different knockdown efficiencies not correlated to monovalent affinities have also been reported by others.^[@cit0075]^ An anti-erbB2 antibody has been reported to bind to its target if transported to the cell surface but not within the cell^[@cit0146]^ and the reasons for this are not fully understood. The exact reasons for these differences are not yet fully clear, but it can be assumed that individual differences in the epitopes play a key role. Alternatively, the local biochemical milieus may influence individual epitope/idiotype combinations. Study of these parameters in the future is needed, as the results will allow pre-selection of the intrabodies accordingly. If, for instance, the different pH in the Golgi does not allow binding of the ER intrabody to its target in this compartment, in vitro antibody selection strategies such as phage display could easily be adapted by carrying out the selection procedure under buffer conditions that mimic those in the Golgi.

In spite of numerous examples for the successful application of ER intrabodies that can be found in literature ([**Table 3**](#t0003){ref-type="table"}, ref. 3), the majority of these reports mainly focus on the analysis of phenotypical effects and on study of a particular target. Questions concerning the intrinsic properties of the ER intrabody technology and the underlying principles that determine success or failure of ER intrabody-mediated knockdowns have not been satisfactorily addressed so far. For wider and more systematic application of the ER intrabody technology, further insight into the parameters influencing the success of the method itself is needed. A more detailed characterization of the ER intrabody knockdown process will allow elimination of potential off-target effects when interpreting results and identification of specific properties of ER intrabody-mediated knockdowns. Opening new ways of analysis, in addition to the already known unique advantages of ER intrabodies over other methods, is critical. Table 3.**A.** Reports of ER intrabody mediated knockdownTargetCell lineBiochemical knockdown detectionPhysiological knockdown readoutRef.ErbB2ErbB2 transformed NIH/3T3 (clone 3.7)Cell surface staining (Flow cytometry)Phosphotyrosine analysis (WB), analysis of growth inhibition and morphologyBeerli 1994b[@cit0150]ErbB2ErbB2 transformed NIH/3T3 (clone 3.7)Cell surface staining (Flow cytometry)Phosphotyrosine analysis (WB), analysis of growth inhibition and morphologyBeerli 1994b[@cit0150]EGFREGFR transformed NIH/3T3No cell surface staining performed, effect of intrabodies on total cellular amount of target was analyzedEGF induced colonies in soft agarBeerli 1994a[@cit0155]ErbB2T47D cellsCell surface staining (Flow cytometry)ErbB2 tyrosine phosphorylation abolished after EGF treatment (no phosphorylated ErbB2 detectable in WB), 46% reduction of EGFR phosphotyrosine following EGF treatment, following NDF treatment ErbB-3 phosphotyrosine reduced by 89%. Phosphorylation states of various proteins. Reduction of NDF induced soft agar growthGraus-Porta 1995[@cit0147]IL-2 RαJurkat cells with induced IL-2 Rα expressionCell surface staining with the same antibody clone like the ER-intrabody (Flow cytometry), pulse chase experiment -- detection of only the immature target in the presence of the ER-intrabody, endoglycosidase H sensitivity of target (consistent with localization in pre- or early Golgi compartment)NoneRichardson 1995[@cit0148]Anti-Integrin VLA4RD rhabdomyosarcoma cells, Jurkat cellsCell surface staining and flow cytometryNumber of adhering cells as functional assay, cell adhesion, cell spreadingYuan 1996[@cit0152]EGFREGFR transformed NIH/3T3 fibroblast cells (NE1), IL-3 dependent FDC-P1 hematopoietic cell line (FE5) (note: activation of EGFR replaces IL-3 dependent growth)Not determined for scFv225RNot determined for scFv255**R** , EGF dependent cell growth reduced by 80% (FE5 cells) or 50% (NE1 cells) by scFv255**S**Beerli 1996[@cit0141]ErbB2ErbB2 transformed NIH/3T3 (clone 3.7)No cell surface staining performedAnchorage independent growth, ability to form tumors in nude miceBeerli 1996[@cit0141]IL-2 RαT cell line Kit225\
HTLV-I transformed cell lines (C8166--45 and HUT102)\
JurkatCell surface staining with the same antibody clone like the ER-intrabody. Cell surface stainings were also repeated with an antibody that recognizes a different epitope than the ER intrabody.Proliferative responseRichardson 1997[@cit0151]alphaV integrinSaos-2Cell surface staining and analysis by flow cytometryCell adhesion, cell spreadingKoistinen 1999[@cit0225]CCR5HEK293T\
Cos 7\
PM1Cell surface staining and analysis by flow cytometryCCR5 dependent cell fusion was prevented by the ER intrabody, protection of PM1 cells from R5 HIV-1 infection by the ER intrabodySteinberger 2000[@cit0217]Procathepsin LHuman melanoma cell line A375SMImmunoblots of cell culture supernatant (target is secreted)Complement lysis assayGuillaume-Rousselet 2002[@cit0208]Folate receptorIGROV-1, SKOV3Cell surface staining and analysis by flow cytometryCell proliferation, morphology, cell adhesionFigini 2003[@cit0207]CCR5SupT cells stably transfected with the target, PM1 cells, primary monocyte derived macrophages (MDMs) and microglial cellsCell surface staining and analysis by flow cytometryHIV infection assaysCordelier 2004[@cit0219]MHC IHEK293, Primary rat keratinocytesCell surface staining and analysis by flow cytometryCell lysisBusch 2004[@cit0223]VEGF-R2PAE VEGR-R2Cell surface staining and analysis by flow cytometryAngiogenesisBöldicke 2005[@cit0153]VEGF-R2 and Tie-2in vivo gene delivery into nude mice, HUVEC, HMEC-1Cell surface staining and analysis by flow cytometryCell proliferation (in vitro), tumor growth (in vivo)Jendreyko 2005[@cit0088]Tie-2in vivo gene delivery into nude mice, HUVECCell surface staining and analysis by flow cytometryIn vitro cell proliferation assay, Analysis of vessel density (87% reduction of vessel density upon ER intrabody treatment)Popkov 2005[@cit0131]CCR5THP-1, PM1, primary CD4+ T cellsCell surface staining and analysis by flow cytometrySusceptibility of cells to HIV-1 infectionSwan 2006[@cit0218]vIL-6Cos-7Comparison of target content in cell lysate and cell culture supernatant, analysis for colocalization of ER intrabody and target by microscopyNeutralization of the target signaling in the ER analyzed by monitoring STAT3 phosphorylation.Kovaleva 2006[@cit0230]TfRMCF-7Cell surface staining and analysis by flow cytometryAnalysis of proliferation and cell cyclePeng 2007[@cit0233]ApoBHepG2Analysis of the cell culture supernatant for the presence of secreted target, Co-IPAnalysis of albumin secretion into the cell culture mediumLiao 2008[@cit0214]CD147HEK293ACell surface staining and analysis by flow cytometry---Tragoolpua 2008[@cit0229]CD147HeLaCell surface staining and analysis by flow cytometry---Intasai 2009[@cit0234]VCAM1HEK293::VCAM-YFPCell surface staining and analysis by flow cytometryCell adhesion assessed by microscopyStrebe 2009[@cit0149]TLR2HEK293, RAW264.7, primary macrophagesCell surface staining and analysis by flow cytometryTNF-alpha releaseKirschning 2010[@cit0004]HBV precore antigenpTRE\
AD38\
HepG2.2.15Analysis of ER intrabody and target localization by fluorescence microscopyReduction of extracellular HBeAg in pTRE precore and HepG2.2.15 cells.Walsh 2011[@cit0213]p75NTRPC12 and NSC19 cellsCell surface staining and analysis by flow cytometryBcl^-^xL mRNA expression, cell differentiation (neurite outgrowth)Zhang 2012[@cit0075]TLR9HEK293, RAW264.7Co-IP, analysis by microscopy for colocalization with an ER markerAnalysis of TLR9 challenge by NF-kappa B reporter assay, TNF-alpha response upon treatment with TLR agonists analyzed by ELISA and intracellular flow cytometryReimer 2013[@cit0005]VCAM1in vivo, mouse strain C57BL/6NCell surface staining and analysis by flow cytometryanalysis of B-cell distribution over blood and bone marrowMarschall 2014a[@cit0134]Aβ oligomers7PA2 fADcells (CHO cells which express a fADhumanV717FAPP mutant)\
7WD4 cellsCo-immunoprecipitationDephosphorylation of ERK1/2 and CREB is reduced in hippocampal neurons treated with conditioned media of the ER intrabody expressing 7PA2-A13K cells. Effect of the ER intrabody on the mTor pathway in 7PA2-A13K cells, which plays a role in homeostasis and autophagy.Meli 2014[@cit0235]Z α antitrypsinCos-7Co-immunoprecipitation-Ordonez 2015[^3][^4][^5] Table 3.**B.** ER intrabody-mediated knockdown: methodological aspectsTargetexpression target T/S/E\*expression ER intrabody T/S\*origin of bindersAffinityExpression levels/degradation levels/half livesAccumulation or accelerated degradation?Knockdown efficiencyRef.ErbB2SSHybridoma, clone FRP54.2 nM for scFv(FRP5)-ETA construct (Wels et al. 1995), apparent affinity FRP5 (IgG) 0.82 nM (Harwerth et al. 1993)Higher intracellular levels of retained antibodies than secreted antibodies, half-life of ErbB2\* ∼1.5h, ErbB2 \>7h (Reinman et al. 2003)Accumulation of ER intrabodies in ERCell surface expression qualitatively analyzed ,NIH/ErbB2\* cells: 95% growth inhibitionBeerli 1994b[@cit0150]ErbB2SSHybridoma, clone FWP51Apparent affinity FWP51 (IgG) 1.3 nM (Harwerth et al. 1993)Higher intracellular levels of retained antibodies than secreted antibodies, half-life of ErbB2\* ∼1.5h, ErbB2 \>7h (Reinman et al. 2003)Accumulation of ER intrabodies in ERCell surface expression qualitatively analyzed ,NIH/ErbB2\* cells: 80% growth inhibitionBeerli 1994b[@cit0150]EGFRSSHybridoma, mab225Nanomolar (Sato et al. 1983)1--2 x10[@cit0005] EGFR receptors per cell, scFv255 expression not detectable (potentially due to unavailability of optimal detection antibody)Authors conclude retained scFv255 might accelerate degradationCell surface expression not analyzed, 31% EGFR reduction by secreted scFv225**S**, 9% EGFR reduction by retained scFv255**R**Beerli 1994a[@cit0155]ErbB2ESHybridoma, clone FRP54.2 nM for scFv(FRP5)-ETA construct (Wels et al. 1995), apparent affinity FRP5 (IgG) 0.82 nM (Harwerth et al. 1993)qualitatively assessed by WB, NDF induced stimulation of cell growth 2.8 fold in control cells, 1.5 fold stimulation in ER-intrabody transfected cells(Not quantified but WB seems to indicate similar levels of ErbB2 in presence and absence of ER-intrabody → there seems to be neither accumulation nor accelerated degradation)Cell surface expression qualitatively analyzedGraus-Porta 1995[@cit0147]IL-2 Rαinduced in JurkatSHybridoma HD245--332: anti-Tac, HybridomaNot determined in this paperHalf-life of scFv-KDEL more than 30h (pulse chase)Antibody/IL-2Ra complexes are degraded by a nonlysosomal mechanism (= accelerated degradation)Cell surface expression qualitatively analyzed, 16 of 16 cell clones stably transfected with ER-intrabody showed complete inhibition of target induction, 3of 15 cell clones stably transfected with secreted antibody version also showed downregulation of target but incomplete (remaining 12 clones showed normal or even high levels of the target)Richardson 1995[@cit0148]Anti-Integrin VLA4SSHumanized form (hHP1/2, unpublished) of the mouse mAb mAbHP1/2) (hybridoma)EC50 - 0.015 nM (Hanf et al. 2014)Not quantifiedNot determined52% of stably transfected RD cell clones and 8% of stably transfected Jurkat cells displayed reduced surface expression of the target. Target reduction on the surface of selected RD clones was ∼80%, on the surface of selected Jurkat cells 65--100% (MFI levels used for quantification of knockdown efficiency). 90% of mock transfected but \< 1% of ER-intrabody transfected RD cells were spread.Yuan 1996[@cit0152]EGFRSS^2^Hybridoma, mab225Nanomolar (Sato et al. 1983)Expression levels of scFv225 were much lower than scFv-FRP5 in Cos-1 cells. scFv225 was mainly in the insoluble fraction.Not determined for scFv225RNot determined for scFv225R, EGF dependent cell growth reduced by 80% (FE5 cells) or 50% (NE1 cells) by scFv225SBeerli 1996[@cit0141]ErbB2S^3^S ^2^Hybridoma, clone FRP54.2 nM for scFv(FRP5)-ETA construct (Wels et al. 1995), apparent affinity FRP5 (IgG) 0.82 nM (Harwerth et al. 1993)Expression levels of scFv-FRP5 were much higher than scFv255 in Cos-1 cells.Not determined97% growth inhibition in soft agar, 55% reduced tumor volume after 13 d of growth in nude miceBeerli 1996[@cit0141]IL-2 RαSS and inducibleHybridoma HD245--332: anti-Tac, HybridomaNot determined in this paperHalf-life of IL2Ralpha is greater than 24h (Levin et al. 1997), Full induction of scFv after 24h of tetracycline withdrawal.IL2Ralpha persisted for up to 72h at the cell surface after tetracycline withdrawal. Cell lines normally express more than 200 000 target molecules per cell.While mature form (55 kDa) of the target vanishes, the immature (40kDa) form of the target accumulates2 or more than 2 log units of mean fluorescence intensity (cell surface staining) in all cell lines testedRichardson 1997[@cit0151]alphaV integrinESHybridoma, L230---Not determinedNot determined70--100% decreaseKoistinen 1999[@cit0225]CCR5TTTTTSST6 from phage display of a Fab rabbit immune library, converted to scFv format2.7 nM for ST6 8.5 nM for ST6/34 (humanized version of ST6) ST6 binds to a linear epitope in the first extracellular domain of CCR5[@cit0236]ST6 expressed at higher levels than its humanized version but the humanized version of ST6 led to a slightly higher knockdown efficiency (results from experiments with HEK293T cells transiently cotransfected with target and ER intrabody).[@cit0236]Not determinedDecrease from 66% target positive cells of controls to 5.9% target-positive cells for ST6 ER intrabody expressing cells or 2.7% target-positive cells for ST6/34 ER intrabody expressing cells.[@cit0236]Steinberger 2000[@cit0217]         Procathepsin LETHybridoma clone 3D85×10^--8^ MNot quantifiedIntracellular accumulation of targetPreliminary studies suggested susceptibility to complement lysis was 50% increased if ER intrabody was expressedGuillaume-Rousselet 2002[@cit0208]Folate receptorESHybridoma clone MOV19 Mab7.1×10^--8^ M by displacement study, 1.8×10^--8^ M by scatchard analysismRNA levels for the ER intrabody were highest in the IGROV-1 clone with the most efficient target knockdownAccelerated degradation of the target upon ER intrabody expression (determined by western blot of whole cell lysates)IGROV-1 clones with 60 (=DM60), 85 (=DM85) and 99% (=DM99) reduction, ER intrabody transfected SKOV3 were negative for surface target. Reduction of cell surface target remained stable over 1 y of culture in DM99, but spontaneous decrease in target expression was observed in DM60 and DM85Figini 2003[@cit0207]CCR5SESHybridoma, CTC8, antibody 2C7---Very high expression in SupT/CCR5 cells, target expression in \<75% of PM1 cells, target expression in \<50% of MDMsNot quantified50--60% reduction of surface targetCordelier 2004[@cit0219]MHC IESTHybridoma, clone OX-18---With increasing ER intrabody expression, the cell surface expression of the target decreased (indicated by flow cytometric analysis). Down-regulation of cell surface target was only observed at ER intrabody expression levels of \>200 U green fluorescence.Intracellular accumulation of targetReduction of specific cell lysis from more than 80% to less than 30% of cells.Busch 2004[@cit0223]VEGF-R2SSPhage display,scFvA2, scFvA73.8 nM (Böldicke et al. 2001)------Not quantifiedBöldicke 2005[@cit0153]VEGF-R2 and Tie-2ESPhage display from an immune library, clone S08b (Popkov et al. 2003) and VR05 (Popkov et al. 2004)2S08b: 1nM(Popkov et al. 2003)VR05: 3 nM (Popkov et al. 2004)Not determinedNot determined98.6% reduction of VEGF-R2 surface expression and 91.2% reduction of Tie-2 surface expression in HUVEC ; 92.1% reduction of VEGF-R2 and 92.5% reduction of Tir-2 cell surface expression in HMEC-1 cellsJendreyko 2005[@cit0088]Tie-2ESPhage display from an immune library, clones 1S05 and 2S03 (Popkov et al. 2003)---Not determinedNot determined80--90% reduction of cell surface expression of the targetPopkov 2005[@cit0131]CCR5ESPhage display from an immune library, clone ST6/348.5 nM (Steinberger et al. 2000)Not determinedNot determinedNot quantifiedSwan 2006[@cit0218]vIL-6TTPhage display with naïve library (Tomlinson), monoclona l anti-vIL-6 (MAV)340 nMNot quantifiedNot quantified30% reduction or 69% reduction of phospho-STAT3 if 0.5 μg or 0.25 μg of target-vector DNA were transfected.Kovaleva 2006[@cit0230]TfREThybridoma---Not determinedNot determined83% reduced surface expression of the target at 72h after transfection with the ER intrabodyPeng 2007[@cit0233]ApoBESHybridoma clone 1D1 and 1C4---Not quantifiedNot determinedNot quantifiedLiao 2008[@cit0214]CD147ETHybridoma, clone M6--1B9---Not determinedNot determined13% of ER intrabody transduced cells were positive for the target while 28% of untransduced and 29% of mock-transduced cells were positive for the target (36h after transduction)Tragoolpua 2008[@cit0229]CD147ETHybridoma, clone M6--1B9---not determinedNot determinedNot quantifiedIntrasai 2009[@cit0234]VCAM1STHybridoma clone 6C7.1---not determinedNot determined43% of cells were negative for VCAM1 48h after transfection with the ER intrabody, 94 % after 96hStrebe 2009[@cit0149]TLR2TEETSSHybridoma clone T2.5------Intracellular accumulation of targetComplete knockdownKirschning 2010[@cit0004]HBV precore antigenSTImmunoglobulin new antigen receptor (IgNAR) single domain antibody VNAR H6 isolated by phage display from a shark library53 nM for HBeAgNot quantifiedSlight intracellular accumulation of p25/p17 in AD38 cells, slight reduction of intracellular p25 in pTRE precore and HepG2.2.15 cellsIn pTRE precore cells ER intrabody expression resulted in 0.9 fold reduced intracellular p25 levels and 0.3 fold reduction of p17 HBeAg. In secretion incompetent AD38 cells, ER intrabody expression led to a slight increase (1.1-1.2 fold) in p25. In HepG2.2.15 intracellular p25 was reduced 0.6-0.8 fold and secretion of p17 HBeAg was reduced 0.5 fold upon ER intrabody expression.Walsh 2011[@cit0213]p75NTRETphage display from a naïve library, clones SH325-A11, SH325-B6, SH325-G7SH325-A11: 6.5×10^--9^SH325-B6: 3.9×10^--9^SH325-G7:3.9×10^--8^SH325-A11 and SH325-B6: 5--10 ng ER intrabodies per 10^6^ cells, SH325-G7:\>15 ng ER intrabodies per 10^6^ cellsNot determined56% reduction of cell surface target after 96h (maximal knockdown efficiency was reached 96h after transfection with the ER intrabody plasmid)Zhang 2012[@cit0075]                  TLR9T and ETHybridoma clone 5G5Not determinedNot determinedNot determinedNot determinedReimer 2013[@cit0005]VCAM1ESHybridoma clone 6C7.1Not determinedNot quantifiedNot determinedCell surface stainings suggested complete depletion of cell surface VCAM1 in bone marrow cells but absence of the lethal phenotype expected for the complete knockout of VCAM1 hinted at the potential presence of traces of residual VCAM1cell surface expressionMarschall 2014a[@cit0134]Aβ oligomersSSscFvA13 selected by IACT in yeastNot determinedER intrabody levels were unchanged after treatment with proteasome inhibitor for 6h suggesting degradation does not occur via ERAD, but the ER intrabody had a short half-life, being almost completely degraded after 6 hNo intracellular accumulation of Aβ. Steady state levels of APP and APP C-terminal fragments were similar in control and ER intrabody expressing cells.60--70% reduction of secreted Aβ dimers and trimers upon expression of the ER intrabody (detected in concentrated conditioned media), 70--80% reduction of secreted oligomeric conformers, increase in monomeric species was observedMeli 2014[@cit0235]Z α antitrypsinTTHybridoma clone mAb4B12Not determinedER Intrabodies were expressed at level comparable to those of the targetTarget accumulates upon ER intrabody expression (compared to cells that express a secreted antibody). No marked ER stress was found upon ER intrabody expression and degradation of the ER-intrabody-target complex by proteasomal or autophagic pathways was not observed.Intracellular polymerization of Z α antitrypsin was reduced by 60%, secretion of Z α antitrypsin was reduced in scFv4B12-KDEL expressing cells and secretion was increased in scFv4B12 expressing cells.Ordonez 2015[^6][^7][^8]

In the following, we review ER intrabody-mediated knockdown studies with a particular focus on methodological aspects ([**Table 3A and 3B**](#t0003){ref-type="table"}). The first example of in vivo efficacy of ER intrabodies has recently been described,^[@cit0134]^ but ER intrabody-mediated knockdowns have so far been employed in vitro^[@cit0003]^ in a large variety of setups. ER intrabody mediated knockdowns have been performed either in cell lines with constitutive^[@cit0075]^ or inducible^[@cit0148]^ endogenous expression of the target or in cell lines that had been either transiently^[@cit0149]^ or stably^[@cit0141]^ transfected with the target. Correspondingly, transfection of ER intrabodies into these cell lines has been performed transiently,^[@cit0075]^ inducibly stable^[@cit0151]^ or constitutively stable.^[@cit0151]^ A significant quantitative biochemical analysis of the involved parameters is lacking in most studies published so far. Further, the information on the knockdown process has come from very diverse assays usually optimized for one target, which prevents a systematic analysis of these datasets to obtain general conclusions.

Hence, it is currently difficult to attribute knockdown efficiencies to the biochemical properties of the respective intrabody, e.g., affinity, because knockdown efficiency may also be influenced by the particular expression levels of the ER intrabody and its antigen. Individual developments of transient expression levels over time will also surely affect the knockdown efficiency and a respective time dependence of knockdown efficiency after transient transfection of ER intrabodies has been observed.^[@cit0149]^

Despite the lack of a systematic analysis of these important parameters, we can nevertheless gain some valuable insights from some examples. For instance, the analysis of 3 different ER intrabodies transiently expressed in the same cell line against the same target allowed some interesting observations.^[@cit0075]^ The ER intrabodies in this study were analyzed for affinity, expression levels and their ability to bind a linear or conformational epitope. Interestingly, the ER intrabody with the lowest affinity but the highest expression levels gave rise to the highest knockdown efficiency,^[@cit0075]^ underlining once more the need for further understanding of the knockdown process in a quantitative manner. Moreover, while all antibodies in this study recognized the native target on the cell surface, the ER intrabody with the highest knockdown efficiency also efficiently recognized a linear epitope.^[@cit0075]^ Recognition of a linear epitope of an unfolded or only partly folded protein, possibly already while the protein is still in the process of translation into the ER, can be imagined to efficiently interfere with the folding process and in this way accelerate degradation of this protein. A systematic characterization of ER intrabody epitopes, particularly of ER intrabodies that are known to accelerate degradation of the target, will in the future be required to evaluate this hypothesis. If the recognition of linear epitopes by ER retained antibodies can indeed promote accelerated degradation of target proteins, this mechanism may in the future be harnessed by selectively generating antibodies against short linear peptide sequences within the target protein instead of whole proteins, and would also allow an important acceleration of the method since the necessity for antigen protein production -- the single most retarding process in today\'s antibody generating pipelines -- can be completely avoided.

An important question to understand intrabody generated phenotypes and to avoid incorrect conclusions due to unspecific and off-target effects is for the fate of the intrabody/target protein complex. Only few studies are available so far which tried to assess these questions. It was shown that the ER intrabodies targeting ß-amyloid precursor protein (APP) and the anti-TLR2 ER intrabody are degraded by the proteasome (Ref. ^[@cit0154]^, Böldicke and Burgdorf, unpublished). Although ER intrabodies have been reported to cause accelerated degradation of a target protein,^[@cit0155]^ there are also reports on accumulation of the target within the cell, although it is depleted from the surface.^[@cit0150]^ The determining factors that are responsible for accelerated degradation, accumulation or even unchanged intracellular target levels are still not clear. However, no detectable ER stress response (unfolded protein response) was observed following substantial overexpression of an anti-p75NTR ER intrabody, confirming the specificity of this particular approach^[@cit0075]^ and recommending measurement of UPR as a good control allowing for rating the relevance of any future intrabody approaches. Another observation, with possible relevance to the question of the post-translational fate of intrabodies and their antigens, is the lack of target protein glycosylation upon expression of an ER intrabody as a result of the retention in the ER.^[@cit0148]^

To compare the results of different ER intrabody-mediated knockdowns, the choice of methods used for detecting knockdowns is critical. The heterogeneity of analysis methods used so far is therefore an obstacle for correlating antibody properties with knockdown efficiency. Methods for detection of ER intrabody-mediated knockdowns ranged from proof on the biochemical level by cell surface stainings followed by flow cytometry to a variety of functional assays including entirely qualitative analysis (see [**Table 3A and 3B**](#t0003){ref-type="table"}). While flow cytometric analysis of cell surface stainings are preferable to other methods because they provide direct biochemical evidence for a potential membrane expression knockdown, cell surface stainings have also not been done in a standardized way. In some reports, the same antibody clone that was used as an ER intrabody was also used for the detection of the target on the cell surface,^[@cit0148]^ which bears the risk of artifacts due to ER intrabodies that still mask the target protein\'s epitope on the cell surface after being released by cell lysis. Although retention by the KDEL receptor has been described to be very efficient (retention of a 10-fold molar excess of substrate may be possible^[@cit0156]^), masking of target proteins on the cell surface due to secretion of ER intrabodies must be excluded. In order to avoid this artifact, cell surface stainings have therefore increasingly been performed with detection antibodies that have been mapped to bind to a different epitope than the ER intrabody.^[@cit0075]^

In conclusion, although there are already initial findings that suggest a link between particular antibody properties and knockdown efficiency, a more systematic analysis of these links is required to allow better a priori predictions, and thus to allow the selection of optimal antibodies for future intrabody knockdown approaches.

The ER Intrabody Approach in Comparison to other Knockdown Methods {#s0008}
==================================================================

The cell surface and its receptors provide an interface for communication between the individual cell and its environment, and is therefore a crucial element of cellular decision processes, determining the organization and function of cells, tissues and organs. Complementary to cell surface receptors, secreted factors control cellular decisions by transducing signals via transmembrane receptors to the inside of the cell. Because both the soluble extracellular factors as well as cell surface receptors pass the secretory pathway, the ER intrabody technology can be employed to systematically target these crucial control elements at the protein level.

There have been other attempts to target these proteins at the post-translational level by pharmacological inhibition of receptor tyrosine kinases,^[@cit0157]^ blocking cell surface receptors or secreted factors extracellularly with antibodies^[@cit0158]^ or even by targeting the intracellular part of cell surface receptors or signaling molecules downstream of the cell surface receptors via cytosolic intrabodies^[@cit0011]^ or phosphopeptide mimetics.^[@cit0160]^ Most of these approaches have very narrow application ranges and require tedious individual developments for every case. For instance, not all of the cell surface receptors are receptor tyrosine kinases, and therefore not all of them are accessible to the respective pharmacological agents, and pharmacological inhibitors are only available for some of the receptor tyrosine kinases. The same is true for phosphopeptide mimetics: inhibitory and at the same time cell permeable drugs are only available for a very small number of the signaling molecules, allowing only specialized applications.

Another drawback of pharmacological agents for protein inhibition is the dependence of their effectiveness on biodistribution and bioavailability and the potential side effects that may occur due to lack of specificity, especially as tyrosine kinase inhibitors are generally less specific than antibodies,^[@cit0162]^ which for example, has been shown for protein kinase inhibitors and inhibitory oligonucleotides of TLRs. It was shown that the compounds KT5720, Rottlerin and quercetin inhibited many different protein kinases.^[@cit0164]^ Inhibitory CpG comprising oligonucleotides developed to inhibit the function of TLR9 inhibit TLR9 signaling, but also bind signal transducer and activator of transcription 1 and 4 (STAT1 and STAT4) and interact with TLRs 3, 7 and 8.^[@cit0165]^ Finally, there is no systematic way to generate them for any possible protein, very much in contrast to antibodies, which can be rationally and systematically generated to almost any target within a few weeks.^[@cit0167]^

Dominant negative mutants (for review see Ref. ^[@cit0168]^) interfere with protein function by competing with the wildtype, and usually require detailed knowledge of the role of individual amino acids in the protein function. In addition, its dependence on vast overexpression is prone to cause unspecific effects and cell stress. Intrabody approaches do not require any knowledge of the target protein, but even may be used to reveal phenotypes of yet completely unknown proteins, because they can be generated from the genomic sequence information of unknown open reading frames (ORFs), without requiring the antigen for their generation, e.g., by the well-established method of phage display based on synthetic peptides.^[@cit0169]^

The application range for antibody-based targeting of the cytosolic part of kinase receptors and of the corresponding signaling molecules downstream of cell surface receptors similarly suffers from limitations. As described above, antibodies that can fold correctly if expressed in the cytosol are not easily obtained^[@cit0019]^ and, although the delivery of antibodies as proteins to the cytosol has been demonstrated in vitro,^[@cit0024]^ protein delivery from the outside still remains a challenge. ER intrabodies, in contrast, are generally applicable both in vitro and in vivo and can be generated with high specificity against any protein of the secretome, provided that the target protein or a sufficient fragment of it (e.g., synthetic peptide) are available for the selection procedure.^[@cit0060]^ In vivo studies by ER intrabody gene delivery include knockdown in xenograft tumor models and in an Alzheimer\'s disease mouse model.^[@cit0088]^ The successful in vivo protein knockdown in transgenic intrabody mice by ER intrabodies has opened new opportunities to study genetically lethal phenotypes.^[@cit0134]^ If the hypothesis can be confirmed that the strength of the in vivo knockdown can be influenced by the strength of an exogenous promoter, different or inducible promoters in mice will certainly facilitate the establishment of novel disease-related preventive and therapeutic mouse models. The potential for intrabody expression restricted to specific tissues by appropriate promoters will yield new insights into the in vivo function of new proteins in subpopulations of cells. Although blocking cell surface receptors by secretion of antibodies to the cellular environment is broadly applicable to cell culture and has also been performed in vivo in transgenic mice,^[@cit0159]^ this type of interference at the protein level is little defined because the location of the effect in vivo can only poorly be controlled. Since secreted antibodies can be transported to different locations in a transgenic mouse, a secreted antagonistic antibody may not only have an autocrine and paracrine, but also an endocrine effect, which renders tissue specific knockdowns at the protein level impossible by this method.

The most commonly used techniques to knock down proteins of the secretome are so far not those taking action at the post-translational level, but methods that take effect at the RNA or DNA level. RNA interference (RNAi) has become a widely used standard method for knocking down proteins as it is generally applicable provided that the sequence of the target mRNA is known. Only a short RNA sequence (short interfering RNA, siRNA) that can induce degradation of all the homologous cellular mRNA as part of an RNA induced silencing complex (RISC) is required.^[@cit0171]^ Generating siRNA technically was less challenging and less time-consuming than ER intrabody generation by the hybridoma technology, but this situation is currently changed due to the availability of automated miniaturized in vitro antibody selection methods, which provide the antibody gene in the correct format (scFv) for immediate subcloning.

Consequently, the increasing availability of antibody genes and efforts to generate databases with detailed descriptions for affinity reagents^[@cit0060]^ can in the future provide a well-annotated resource of already existing antibody genes that are ready to use as ER intrabodies. For these "ready to use" antibody genes, which are available in the thousands already, generating a knockdown with the ER intrabody will not require any more time than is required for an RNAi-based approach. Although confirmation by a larger data set is needed, a claimed advantage of the ER intrabody technology over RNAi is the potentially longer half-life of the protein-based ER intrabodies compared to RNA-molecules.^[@cit0175]^ Another inherent property of ER intrabodies that represents an advantage over RNAi concerns specificity, which can be thoroughly assessed biochemically by a multitude of assays before applying an antibody intracellularly, while specificity and off-target effects of RNAi are often more difficult to predict.

RNAi, which is thought to have its origins in nature from an antiviral defense mechanism,^[@cit0176]^ has been found to cause several off-target effects, including an interferon response^[@cit0179]^ and aberrant expression of up to more than 1000 genes as found by Persengiev et al.^[@cit0181]^ Off-target silencing of siRNA/shRNA results from imperfect pairing of siRNA strands with sequence motifs that reside primarily in 3′ UTR regions of cellular mRNA. siRNA and miRNA share the same silencing machinery and the magnitude of regulation of siRNA off-target transcripts is similar to that of micro RNAs.^[@cit0184]^ Furthermore, siRNA recognize TLR3, TLR7 and TLR8 resulting in secretion of interferon-α and synthesis of pro-inflammatory cytokines.^[@cit0185]^ RNAi and the ER intrabody technology both have broad application areas as they both can be applied in vitro and in vivo. Applications *in vivo* have already been performed both for RNAi and the ER intrabody technology in the form of in vivo delivery^[@cit0088]^ and in the form of transgenic mice.^[@cit0134]^ However, therapeutic applications are hampered by the hurdle posed by the need for efficient in vivo delivery of nucleic acids, and are still subject to safety concerns for both RNAi and the ER intrabody technology.^[@cit0175]^ Consequently, applications have primarily focused on use of the technologies as research tools. The same is true for the classic knockout strategies at the DNA level.

Genetic knockouts in mice have greatly contributed to a better understanding of human disease, and, as a consequence, can yield new therapeutic approaches. However, in spite of substantial efforts aimed at cataloging the mammalian genome, e.g., the International Mouse Phenotyping Consortium ([www.mousephenotype.org](www.mousephenotype.org)), genetic knockouts do not always allow complete analysis of essential genes because approximately 30% of genetic knockouts are embryonically lethal.^[@cit0191]^ If a complete knockout of a gene is lethal early in development, alternative strategies for functional knockdown are required to study functions of the gene in later developmental stages and adults. ER intrabodies offer a solution. Although the genetic knockout of the cell adhesion molecule VCAM1 leads to early embryonic death, mice with an anti-VCAM1 ER intrabody exhibited depletion of VCAM1 at the cell surface, but were nevertheless viable.^[@cit0134]^ This demonstrates the potential of the ER intrabody technology as an alternative strategy for studying the phenotype of embryonically lethal knockouts in adult mice.

In conclusion, the inherent properties of ER intrabodies implicate some limitations, but also specific strengths that can serve to compensate shortcomings of the other established technologies for functional studies of the secretome.

The Promising Future of Intrabody Approaches {#s0009}
============================================

Although intrabody approaches have been known for more than a quarter of a century, and the above examples are very encouraging, this approach is not as widely used for cell biological research as could be expected given the possible benefits. In particular, the technology had a very slow start. What is the reason for that? The answer is not simple, and comprises a multitude of factors. The first intrabody studies used microinjection of mRNA, a cumbersome and inefficient method of limited specificity, resulting in a first decade of very rare applications. In the early nineties, the method gained some momentum with the advent of essential technological elements like the single chain format and recombinant antibody technologies. Typical applications followed the cytoplasmic intrabody approach. In light of the quite substantial requirements of getting an antibody combining both functional neutralization of its target and correct folding in reducing milieu, it can be assumed that those candidates were not easily identified from the collection of available hybridomas. In the early days of intrabody technology, a substantial number of intrabody trials may have failed due to the limited availability of suitable monoclonal antibodies and the limited knowledge about the biochemical requirements. Further, generating recombinant scFv antibodies from hybridoma, and particular expressing it in *E. coli* for functional validation, was a technology not widespread among the typical cell biology lab of the time. Quite a number of scFvs generated from hybridoma showed very poor production yields in *E. coli*,^[@cit0192]^ generating substantial problems for the necessary biochemical characterizations. Another problem, which originated from the use of early hybridoma cell lines as sources for the isolation of antibody DNA, was the frequently observed expression of multiple antibody mRNAs in these cells due to the aneuploid/deregulated state of the hybridoma cells, lacking allelic exclusion and allowing accumulation of mutations.^[@cit0193]^ This mandated substantial experimental efforts to confirm that the predominant V region PCR bands found from any hybridoma indeed encoded the V region subset providing the specificity identified in the supernatant.^[@cit0197]^ These factors contributed to give the intrabody technology a mixed reputation among the typical possible users who were not acquainted with recombinant antibody technology. Nevertheless, successful projects using hybridoma cells as a starting point accumulated over time and provided a slow but steady development of the technology.

Only in the last decade have recombinant *in vitro* antibody selections from gene repertoires been utilized in substantial numbers, allowing much quicker access to the antibody and providing the V region encoding DNA without any additional experimental effort. This also substantially increases the chances of getting antibodies with the required complex property combination using appropriately tuned libraries and panning strategies from the start. The technology to generate research antibodies from phage display in large numbers is now robust and reliable,^[@cit0065]^ and international research consortia like the "Affinomics" initiative ([www.affinomics.org](www.affinomics.org)) in the EU and similar initiatives in the US have already generated several thousands of antibodies to hundreds of new potential intrabody targets together with their V region genes, providing right away a vast resource of scFv DNA for future intrabody approaches. Studies on introducing antibodies from the outside to interfere with intracellular functions show the limitations of this approach,^[@cit0024]^ so the quick availability and fast generation of recombinant antibodies for intrabody approaches may motivate more researchers to try this technology for their functional analysis. Protein functions of bioinformatically predicted ORFs of so far unknown function could be evaluated in respect of resulting knockout phenotypes, even without the availability of the resulting protein, because antibodies can efficiently be generated by phage display to chemically synthetized peptides based on the ORF sequence. In the future, this strategy allows a completely new systematic approach to identify protein functions of yet uncharacterized members of the proteome, particularly straightforward for the membrane proteome where most binders may be able to generate a phenotype after just a single subcloning step into an ER intrabody vector. Further, new methods for the rapid generation of transgenic organisms, like CRISPR/Cas9 or TALEN, are maturing, and will further facilitate the experiments required to screen for a phenotype in vivo.

The application of the intrabody technology, in particular the most facile ER intrabody approach, can thus be expected to grow much more rapidly in the near future than in its first 2 decades.
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